Supernus Files 8-K on Financial Results and Exhibits
Ticker: SUPN · Form: 8-K · Filed: 2024-02-13T00:00:00.000Z
Sentiment: neutral
Topics: earnings, financial-reporting, 8-K, disclosure
TL;DR
**Supernus Pharmaceuticals just filed an 8-K regarding its financial results and statements, signaling an upcoming or concurrent earnings disclosure.**
AI Summary
Supernus Pharmaceuticals, Inc. filed an 8-K Current Report with the SEC on February 13, 2024. This filing, with accession number 0001356576-24-000006, specifically addresses 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'. The report indicates the company is disclosing its financial performance and related documents as of the earliest event reported date, February 13, 2024.
Why It Matters
This 8-K signals that Supernus Pharmaceuticals is providing an update on its financial performance, which is crucial for investors to assess the company's health and future prospects. It often precedes or accompanies an earnings release, offering transparency into the company's operational results.
Risk Assessment
Risk Level: medium — The filing itself is a standard disclosure for financial results; the risk level depends entirely on the actual financial performance, which is not detailed in this filing text.
Key Numbers
- N/A — Financial Results (No specific dollar amounts or financial figures are provided in this filing text, only the nature of the disclosure.)
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — registrant
- SEC (company) — regulatory body
- Delaware (company) — state of incorporation
- Rockville (company) — city of business address
FAQ
What is the purpose of this 8-K filing by Supernus Pharmaceuticals, Inc.?
This 8-K filing reports on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' for Supernus Pharmaceuticals, Inc.
What is the earliest event reported date for this filing?
The earliest event reported date for this filing is February 13, 2024.
What is the full legal name of the company making this filing?
The exact name of the registrant as specified in its charter is Supernus Pharmaceuticals, Inc.
What is the Commission File Number for Supernus Pharmaceuticals, Inc.?
The Commission File Number for Supernus Pharmaceuticals, Inc. is 001-35518.
Where is Supernus Pharmaceuticals, Inc.'s principal executive office located?
The principal executive offices of Supernus Pharmaceuticals, Inc. are located at 9715 Key West Ave, Rockville, MD 20850.
Filing Stats: 494 words · 2 min read · ~2 pages · Grade level 9.2 · Accepted 2024-02-13 16:08:43
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Sto
Filing Documents
- supn-20240213.htm (8-K) — 26KB
- ex99102-13x2024.htm (EX-99.1) — 9KB
- image_0.jpg (GRAPHIC) — 5KB
- 0001356576-24-000006.txt ( ) — 167KB
- supn-20240213.xsd (EX-101.SCH) — 2KB
- supn-20240213_lab.xml (EX-101.LAB) — 24KB
- supn-20240213_pre.xml (EX-101.PRE) — 12KB
- supn-20240213_htm.xml (XML) — 3KB
02 Results of Operations and Financial Conditions
Item 2.02 Results of Operations and Financial Conditions. On February 13, 2024, Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report its business results for the fourth quarter and full year of 2023 after the market closes on Tuesday, February 27, 2024. The Company will host a conference call and webcast on Tuesday, February 27, 2024 at 4:30 p.m. E.T. to discuss its fourth quarter 2023 business and financial results. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release dated February 13, 2024 filed as an Exhibit pursuant to Item 2.02 hereof. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SUPERNUS PHARMACEUTICALS, INC. DATED: February 13, 2024 By: /s/ Timothy C. Dec Timothy C. Dec Senior Vice President and Chief Financial Officer 3